INFINITY PHARMACEUTICALS INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch INFIQ and buy or sell other stocks, ETFs, and their options commission-free!

About INFIQ

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. 

CEO
Seth A. Tasker, MBA
CEOSeth A. Tasker, MBA
Employees
Employees
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1995
Founded1995
Employees
Employees

INFIQ Key Statistics

Market cap
100.00
Market cap100.00
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.25K
Average volume1.25K
High today
High today
Low today
Low today
Open price
Open price
Volume
22.25K
Volume22.25K
52 Week high
$0.0026
52 Week high$0.0026
52 Week low
52 Week low

Stock Snapshot

As of today, INFINITY PHARMACEUTICALS INC(INFIQ) shares are valued at $0.00. The company's market cap stands at 100.

On 2026-06-05, INFINITY PHARMACEUTICALS INC(INFIQ) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 22.25K, compared to an average daily volume of 1.25K.

INFIQ News

TipRanks 5d
Paragon Care flags partial Infinity recovery and affirms FY26 earnings outlook - TipRanks

...

Paragon Care flags partial Infinity recovery and affirms FY26 earnings outlook - TipRanks

People also own

Based on the portfolios of people who own INFIQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.